Laura Silvius, Managing Editor

Remibrutinib gains FDA approval as the first oral treatment for chronic hives, offering hope for patients unresponsive to standard therapies.

New research reveals how BCMA mutations in multiple myeloma affect the efficacy of immunotherapy drugs, guiding treatment decisions for patients.

Iberdomide enhances chimeric antigen receptor (CAR) T-cell therapy effectiveness in multiple myeloma, boosting immune response and cell functionality.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Promising phase 2 results for taletrectinib in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.

Experts forecast a potential resurgence of measles and other vaccine-preventable diseases in the U.S. due to declining vaccination rates.